Injectable materials for the treatment of myocardial infarction and heart failure: the promise of decellularized matrices

J Cardiovasc Transl Res. 2010 Oct;3(5):478-86. doi: 10.1007/s12265-010-9202-x. Epub 2010 Jul 15.

Abstract

Cardiovascular disease continues to be the leading cause of death, suggesting that new therapies are needed to treat the progression of heart failure post-myocardial infarction. As cardiac tissue has a limited ability to regenerate itself, experimental biomaterial therapies have focused on the replacement of necrotic cardiomyocytes and repair of the damaged extracellular matrix. While acellular and cellular cardiac patches are applied surgically to the epicardial surface of the heart, injectable materials offer the prospective advantage of minimally invasive delivery directly into the myocardium to either replace the damaged extracellular matrix or to act as a scaffold for cell delivery. Cardiac-specific decellularized matrices offer the further advantage of being biomimetic of the native biochemical and structural matrix composition, as well as the potential to be autologous therapies. This review will focus on the requirements of an ideal scaffold for catheter-based delivery as well as highlight the promise of decellularized matrices as injectable materials for cardiac repair.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Biocompatible Materials
  • Cardiac Catheterization
  • Cell Differentiation
  • Cell Proliferation
  • Cell Transplantation
  • Heart Failure / pathology
  • Heart Failure / physiopathology
  • Heart Failure / therapy*
  • Humans
  • Injections
  • Myocardial Infarction / pathology
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / therapy*
  • Myocardium / pathology*
  • Regeneration*
  • Regenerative Medicine*
  • Tissue Scaffolds*
  • Translational Research, Biomedical

Substances

  • Biocompatible Materials